FDA Rejects Duchenne Treatment Claim

The FDA rejected Capricor's claim that its stem cell treatment for Duchenne muscular dystrophy met Phase 3 trial objectives. The decision comes amid GSK cost-saving measures in the pharmaceutical industry.